Membrane lipid interactions in intestinal ischemia/reperfusion-induced Injury

Clinical Immunology

Volumn 153, Issue 1, 2014, Pages 228-240

  Slone, Emily Archer ^a   Fleming, Sherry D ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Ischemia; ; Lipids; ; Neo antigen; Reperfusion;

Indexed keywords

ANTIBODY; ANTIGEN; CARRIER PROTEIN; COMPLEMENT; ICOSANOID; MEMBRANE LIPID; MEMBRANE PROTEIN; PHOSPHOLIPID; SCRAMBLASE;

COMPLEMENT SYSTEM; HUMAN; HYPOXIA; INTESTINE ISCHEMIA; MORTALITY; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY;

ISCHEMIA;; LIPIDS;; NEO-ANTIGEN; REPERFUSION;;

ANIMALS; ANOXIA; ANTIBODIES; ANTIGENS; HUMANS; INTESTINES; MEMBRANE LIPIDS; PHOSPHOLIPID TRANSFER PROTEINS; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84901454301     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.04.018     Document Type: Review

References (145)

1. Guan Y., Worrell R.T., Pritts T.A., Montrose M.H. Intestinal ischemia-reperfusion injury: reversible and irreversible damage imaged in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G187-G196.
2. Oldenburg W.A., Lau L.L., Rodenberg T.J., Edmonds H.J., Burger C.D. Acute mesenteric ischemia: a clinical review. Arch. Intern. Med. 2004, 164:1054-1062.
3. Haglund U., Bergqvist D. Intestinal ischemia - the basics. Langenbeck's Arch. Surg. 1999, 384:233-238.
4. Stamatakos M., Stefanaki C., Mastrokalos D., Arampatzi H., Safioleas P., Chatziconstantinou C., Xiromeritis C., Safioleas M. Mesenteric ischemia: still a deadly puzzle for the medical community. Tohoku J. Exp. Med. 2008, 216:197-204.
5. Noda T., Iwakiri R., Fujimoto K., Matsuo S., Aw T.Y. Programmed cell death induced by ischemia-reperfusion in rat intestinal mucosa. Am. J. Physiol. 1998, 274:G270-G276.
6. Haglund U. Gut ischaemia. Gut 1994, 35:S73-S76.
7. Droy-Lefaix M.T., Drouet Y., Geraud G., Hosford D., Braquet P. Superoxide dismutase (SOD) and the PAF-antagonist (BN 52021) reduce small intestinal damage induced by ischemia-reperfusion. Free Radic. Res. Commun. 1991, 12-13(Pt 2):725-735.
8. Stringa P., Lausada N., Romanin D., Machuca M., Cabanne A., Rumbo M., Gondolesi G. Defining the nonreturn time for intestinal ischemia reperfusion injury in mice. Transplant. Proc. 2012, 44:1214-1217.
9. Matyjaszek S.A., Morton A.J., Freeman D.E., Grosche A., Polyak M.M., Kuck H. Effects of flunixin meglumine on recovery of colonic mucosa from ischemia in horses. Am. J. Vet. Res. 2009, 70:236-246.
10. Cook V.L., Jones Shults J., McDowell M.R., Campbell N.B., Davis J.L., Marshall J.F., Blikslager A.T. Anti-inflammatory effects of intravenously administered lidocaine hydrochloride on ischemia-injured jejunum in horses. Am. J. Vet. Res. 2009, 70:1259-1268.
11. Morton A.J., Grosche A., Rotting A.K., Matyjaszek S.A., Blikslager A.T., Freeman D.E. Expression of cyclooxygenase-1 and -2 in the left dorsal colon after different durations of ischemia and reperfusion in horses. Am. J. Vet. Res. 2009, 70:1536-1544.
12. Dabareiner R.M., White N.A., Donaldson L. Evaluation of Carolina Rinse solution as a treatment for ischaemia reperfusion of the equine jejunum. Equine Vet. J. 2003, 35:642-646.
13. Moses T., Wagner L., Fleming S.D. TLR4-mediated Cox-2 expression increases intestinal ischemia/reperfusion-induced damage. J. Leukoc. Biol. 2009, 86:971-980.
14. Sato N., Kozar R.A., Zou L., Weatherall J.M., Attuwaybi B., Moore-Olufemi S.D., Weisbrodt N.W., Moore F.A. Peroxisome proliferator-activated receptor gamma mediates protection against cyclooxygenase-2-induced gut dysfunction in a rodent model of mesenteric ischemia/reperfusion. Shock 2005, 24:462-469.
15. Hilton H., Nieto J.E., Moore P.F., Harmon F.A., Naydan D.K., Snyder J.R. Expression of cyclooxygenase genes in the jejunum of horses during low-flow ischemia and reperfusion. Am. J. Vet. Res. 2011, 72:681-686.
16. Marshall J.F., Blikslager A.T. The effect of nonsteroidal anti-inflammatory drugs on the equine intestine. Equine Vet. J. 2011, 43(Suppl. 39):140-144.
17. Blikslager A.T., Zimmel D.N., Young K.M., Campbell N.B., Little D., Argenzio R.A. Recovery of ischaemic injured porcine ileum: evidence for a contributory role of COX-1 and COX-2. Gut 2002, 50:615-623.
18. Watanabe T., Kobata A., Tanigawa T., Nadatani Y., Yamagami H., Watanabe K., Tominaga K., Fujiwara Y., Takeuchi K., Arakawa T. Activation of the MyD88 signaling pathway inhibits ischemia-reperfusion injury in the small intestine. Am. J. Physiol. 2012, 303:G324-G334.
19. Kawata K., Takeyoshi I., Iwanami K., Sunose Y., Tsutsumi H., Ohwada S., Matsumoto K., Morishita Y. The effects of a selective cyclooxygenase-2 inhibitor on small bowel ischemia-reperfusion injury. Hepato-Gastroenterology 2003, 50:1970-1974.
20. Cook V.L., Meyer C.T., Campbell N.B., Blikslager A.T. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. Am. J. Vet. Res. 2009, 70:992-1000.
21. Stuart M.J. Prostaglandins and hemostasis: an overview. Adv. Pediatr. 1983, 30:321-364.
22. Schror K. Prostaglandins, other eicosanoids and endothelial cells. Basic Res. Cardiol. 1985, 80:502-514.
23. Blikslager A.T., Roberts M.C., Rhoads J.M., Argenzio R.A. Prostaglandins I2 and E2 have a synergistic role in rescuing epithelial barrier function in porcine ileum. J. Clin. Invest. 1997, 100:1928-1933.
24. Egan K., FitzGerald G.A. Eicosanoids and the vascular endothelium. Handb. Exp. Pharmacol. 2006, 189-211.
25. Pope M.R., Hoffman S.M., Tomlinson S., Fleming S.D. Complement regulates TLR4-mediated inflammatory responses during intestinal ischemia reperfusion. Mol. Immunol. 2010, 48:356-364.
26. Slone E.A., Pope M.R., Roth M., Welti R., Fleming S.D. TLR9 is dispensable for intestinal ischemia/reperfusion-induced tissue damage. Am. J. Clin. Exp. Immunol. 2012, 1:124-135.
27. Sparkes B.L., Slone E.E., Roth M., Welti R., Fleming S.D. Intestinal lipid alterations occur prior to antibody-induced prostaglandin E2 production in a mouse model of ischemia/reperfusion. Biochim. Biophys. Acta 2010, 1801:517-525.
28. Turnage R.H., Kadesky K.M., Bartula L., Guice K.S., Oldham K.T., Myers S.I. Splanchnic PGI2 release and "no reflow" following intestinal reperfusion. J. Surg. Res. 1995, 58:558-564.
29. Mangino M.J., Anderson C.B., Murphy M.K., Brunt E., Turk J. Mucosal arachidonate metabolism and intestinal ischemia-reperfusion injury. Am. J. Physiol. 1989, 257:G299-G307.
30. Charo I.F., Shak S., Karasek M.A., Davison P.M., Goldstein I.M. Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. J. Clin. Invest. 1984, 74:914-919.
31. Hawkey C.J., Rampton D.S. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?. Gastroenterology 1985, 89:1162-1188.
32. Scher J.U., Pillinger M.H. The anti-inflammatory effects of prostaglandins. J. Investig. Med. 2009, 57:703-708.
33. Bray M.A. Leukotriene B4: an inflammatory mediator with vascular actions in vivo. Agents Actions Suppl. 1982, 11:51-61.
34. Grosche A., Morton A.J., Graham A.S., Valentine J.F., Abbott J.R., Polyak M.M., Freeman D.E. Mucosal injury and inflammatory cells in response to brief ischaemia and reperfusion in the equine large colon. Equine Vet. J. Suppl. 2011, 16-25.
35. Gayle J.M., Blikslager A.T., Jones S.L. Role of neutrophils in intestinal mucosal injury. J. Am. Vet. Med. Assoc. 2000, 217:498-500.
36. Karasawa A., Guo J.P., Ma X.L., Tsao P.S., Lefer A.M. Protective actions of a leukotriene B4 antagonist in splanchnic ischemia and reperfusion in rats. Am. J. Physiol. 1991, 261:G191-G198.
37. Oliver M.G., Specian R.D., Perry M.A., Granger D.N. Morphologic assessment of leukocyte-endothelial cell interactions in mesenteric venules subjected to ischemia and reperfusion. Inflammation 1991, 15:331-346.
38. Grisham M.B., Granger D.N. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig. Dis. Sci. 1988, 33:6S-15S.
39. Schmeling D.J., Caty M.G., Oldham K.T., Guice K.S. Cytoprotection by diclofenac sodium after intestinal ischemia/reperfusion injury. J. Pediatr. Surg. 1994, 29:1044-1048.
40. Steiner D.R., Gonzalez N.C., Wood J.G. Leukotriene B(4) promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J. Appl. Physiol. 2001, 91:1160-1167.
41. Casillan A.J., Gonzalez N.C., Johnson J.S., Steiner D.R., Wood J.G. Mesenteric microvascular inflammatory responses to systemic hypoxia are mediated by PAF and LTB4. J. Appl. Physiol. 2003, 94:2313-2322.
42. Mangino M.J., Murphy M.K., Anderson C.B. Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury. J. Pharmacol. Exp. Ther. 1994, 269:75-81.
43. Cuzzocrea S., Rossi A., Serraino I., Di Paola R., Dugo L., Genovese T., Caputi A.P., Sautebin L. 5-lipoxygenase knockout mice exhibit a resistance to splanchnic artery occlusion shock. Shock 2003, 20:230-236.
44. Murthy S., Hui-Qi Q., Sakai T., Depace D.E., Fondacaro J.D. Ischemia/reperfusion injury in the rat colon. Inflammation 1997, 21:173-190.
45. Moore R.M., Muir W.W., Bertone A.L., Oliver J.L. Effect of platelet-activating factor antagonist L-691,880 on low-flow ischemia-reperfusion injury of the large colon in horses. Vet. Surg. 1998, 27:37-48.
46. Turnage R.H., LaNoue J.L., Kadesky K.M., Meng Y., Myers S.I. Thromboxane A2 mediates increased pulmonary microvascular permeability after intestinal reperfusion. J. Appl. Physiol. 1997, 82:592-598.
47. Hill J., Lindsay T.F., Ortiz F., Yeh C.G., Hechtman H.B., Moore F.D. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 1992, 149:1723-1728.
48. Eror A.T., Stojadinovic A., Starnes B.W., Makrides S.C., Tsokos G.C., Shea-Donohue T. Anti-inflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin. Immunol. 1999, 90:266-275.
49. Stahl G.L., Xu Y., Hao L., Miller M., Buras J.A., Fung M., Zhao H. Role for the alternate complement pathway in ischemia/reperfusion injury. Am. J. Pathol. 2003, 162:449-455.
50. Arumugam T.V., Magnus T., Woodruff T.M., Proctor L.M., Shiels I.A., Taylor S.M. Complement mediators in ischemia-reperfusion injury. Clin. Chim. Acta 2006.
51. Hart M.L., Ceonzo K.A., Shaffer L.A., Takahashi K., Rother R.P., Reenstra W.R., Buras J.A., Stahl G.L. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J. Immunol. 2005, 174:6373-6380.
52. Zhang M., Takahashi K., Alicot E.M., Vorup-Jensen T., Kessler B., Thiel S., Jensenius J.C., Ezekowitz R.A., Moore F.D., Carroll M.C. Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J. Immunol. 2006, 177:4727-4734.
53. Karpel-Massler G., Fleming S.D., Kirschfink M., Tsokos G.C. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J. Surg. Res. 2003, 115:247-256.
54. Rehrig S., Fleming S.D., Anderson J., Guthridge J.M., Rakstang J., McQueen C.E., Holers V.M., Tsokos G.C., Shea-Donohue T. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J. Immunol. 2001, 167:5921-5927.
55. Williams J.P., Pechet T.T.V., Weiser M.R., Reid R., Kobzik L., Moore F.D., Carroll M.C., Hechtman H.B. Intestinal reperfusion injury is mediated by IgM and complement. J. Appl. Physiol. 1999, 86:938-942.
56. Zhang M., Alicot E.M., Carroll M.C. Human natural IgM can induce ischemia/reperfusion injury in a murine intestinal model. Mol. Immunol. 2008, 45:4036-4039.
57. Weiser M.R., Williams J.P., Moore F.D., Kobzik L., Ma M., Hechtman H.B., Carroll M.C. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 1996, 183:2343-2348.
58. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Immunology 1996, 93:3357-3361.
59. Reid R.R., Woodcock S., Shimabukuro-Vornhagen A., Austen W.G., Kobzik L., Zhang M., Hechtman H.B., Moore F.D., Carroll M.C. Functional activity of natural antibody is altered in Cr2-deficient mice. J. Immunol. 2002, 169:5433-5440.
60. Fleming S.D., Shea-Donohue T., Guthridge J.M., Kulik L., Waldschmidt T.J., Gipson M.G., Tsokos G.C., Holers V.M. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol. 2002, 169:2126-2133.
61. Fleming S.D., Egan R.P., Chai C., Girardi G., Holers V.M., Salmon J., Monestier M., Tsokos G.C. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J. Immunol. 2004, 173:7055-7061.
62. Miyakis S., Giannakopoulos B., Krilis S.A. Beta 2 glycoprotein I-function in health and disease. Thromb. Res. 2004, 114:335-346.
63. Meroni P.L., Raschi E., Testoni C., Parisio A., Borghi M.O. Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun. Rev. 2004, 3:510-515.
64. Fleming S.D., Pope M.R., Hoffman S.M., Moses T., Bukovnik U., Tomich J.M., Wagner L.M., Woods K.M. Domain V peptides inhibit beta2-glycoprotein I-mediated mesenteric ischemia/reperfusion-induced tissue damage and inflammation. J. Immunol. 2010, 185:6168-6178.
65. Tomasi M., Hiromasa Y., Pope M.R., Gudlar S., Tomich J.M., Fleming S.D. Human Β2-glycoprotein I attenuates mouse intestinal ischemia/reperfusion induced injury and inflammation. Mol. Immunol. 2012, 52:207-216.
66. Kulik L., Fleming S.D., Moratz C., Reuter J.W., Novikov A., Chen K., Andrews K.A., Markaryan A., Quigg R.J., Silverman G.J., Tsokos G.C., Holers V.M. Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J. Immunol. 2009, 182:5363-5373.
67. Elvington A., Atkinson C., Kulik L., Zhu H., Yu J., Kindy M.S., Holers V.M., Tomlinson S. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J. Immunol. 2012, 188:1460-1468.
68. Zhang M., Austen W.G., Chiu I., Alicot E.M., Humg R., Ma M., Verna N., Xu M., Hechtman H.B., Moore F.D., Carroll M.C. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3886-3891.
69. Zhang M., Alicot E.M., Chiu I., Li J., Verna N., Vorup-Jensen T., Kessler B., Shimaoka M., Chan R., Friend D., Mahmood U., Weissleder R., Moore F.D., Carroll M.C. Identification of the target self-antigens in reperfusion injury. J. Exp. Med. 2006, 203:141-152.
70. Chan R.K., Verna N., Afnan J., Zhang M., Ibrahim S., Carroll M.C., Moore F.D. Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM. Surgery 2006, 139:236-243.
71. Haas M.S., Alicot E.M., Schuerpf F., Chiu I., Li J., Moore F.D., Carroll M.C. Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc. Res. 2010, 87:618-627.
72. Hicks A.M., DeLong C.J., Thomas M.J., Samuel M., Cui Z. Unique molecular signatures of glycerophospholipid species in different rat tissues analyzed by tandem mass spectrometry. Biochim. Biophys. Acta 2006, 1761:1022-1029.
73. Tyurina Y.Y., Tyurin V.A., Epperly M.W., Greenberger J.S., Kagan V.E. Oxidative lipidomics of gamma-irradiation-induced intestinal injury. Free Radic. Biol. Med. 2008, 44:299-314.
74. Braun A., Treede I., Gotthardt D., Tietje A., Zahn A., Ruhwald R., Schoenfeld U., Welsch T., Kienle P., Erben G., Lehmann W.D., Fuellekrug J., Stremmel W., Ehehalt R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm. Bowel Dis. 2009, 15:1705-1720.
75. Leslie C.C. Properties and regulation of cytosolic phospholipase A2. J. Biol. Chem. 1997, 272:16709-16712.
76. Anderson B.O., Moore E.E., Banerjee A. Phospholipase A2 regulates critical inflammatory mediators of multiple organ failure. J. Surg. Res. 1994, 56:199-205.
77. Clark J.D., Schievella A.R., Nalefski E.A., Lin L.L. Cytosolic phospholipase A2. J. Lipid Mediat. Cell Signal. 1995, 12:83-117.
78. Lister M.D., Deems R.A., Watanabe Y., Ulevitch R.J., Dennis E.A. Kinetic analysis of the Ca2+-dependent, membrane-bound, macrophage phospholipase A2 and the effects of arachidonic acid. J. Biol. Chem. 1988, 263:7506-7513.
79. Lin L.L., Lin A.Y., Knopf J.L. Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6147-6151.
80. Lin L.L., Wartmann M., Lin A.Y., Knopf J.L., Seth A., Davis R.J. cPLA2 is phosphorylated and activated by MAP kinase. Cell 1993, 72:269-278.
81. Schoonderwoerd K., Stam H. Lipid metabolism of myocardial endothelial cells. Mol. Cell. Biochem. 1992, 116:171-179.
82. Rink C., Khanna S. Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke. Antioxid. Redox Signal. 2011, 14:1889-1903.
83. Frasch S.C., Bratton D.L. Emerging roles for lysophosphatidylserine in resolution of inflammation. Prog. Lipid Res. 2012, 51:199-207.
84. Goetzl E.J., Wang W., McGiffert C., Huang M.C., Graler M.H. Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system. J. Cell. Biochem. 2004, 92:1104-1114.
85. Kotarsky K., Boketoft A., Bristulf J., Nilsson N.E., Norberg A., Hansson S., Owman C., Sillard R., Leeb-Lundberg L.M., Olde B. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J. Pharmacol. Exp. Ther. 2006, 318:619-628.
86. Hines O.J., Ryder N., Chu J., McFadden D. Lysophosphatidic acid stimulates intestinal restitution via cytoskeletal activation and remodeling. J. Surg. Res. 2000, 92:23-28.
87. Lum H. Lysophospholipids in the regulation of endothelial barrier function. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L1335-L1336.
88. Matsubara M., Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis 2005, 178:57-66.
89. Chaudhuri P., Colles S.M., Damron D.S., Graham L.M. Lysophosphatidylcholine inhibits endothelial cell migration by increasing intracellular calcium and activating calpain. Arterioscler. Thromb. Vasc. Biol. 2003, 23:218-223.
90. Leventis P.A., Grinstein S. The distribution and function of phosphatidylserine in cellular membranes. Annu. Rev. Biophys. 2010, 39:407-427.
91. Tyurin V.A., Tyurina Y.Y., Kochanek P.M., Hamilton R., DeKosky S.T., Greenberger J.S., Bayir H., Kagan V.E. Oxidative lipidomics of programmed cell death. Methods Enzymol. 2008, 442:375-393.
92. Fadeel B., Xue D. The ins and outs of phospholipid asymmetry in the plasma membrane: roles in health and disease. Crit. Rev. Biochem. Mol. Biol. 2009, 44:264-277.
93. Smrz D., Lebduska P., Draberova L., Korb J., Draber P. Engagement of phospholipid scramblase 1 in activated cells: implication for phosphatidylserine externalization and exocytosis. J. Biol. Chem. 2008, 283:10904-10918.
94. Yamaji-Hasegawa A., Tsujimoto M. Asymmetric distribution of phospholipids in biomembranes. Biol. Pharm. Bull. 2006, 29:1547-1553.
95. Michiels C., Arnould T., Knott I., Dieu M., Remacle J. Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia. Am. J. Physiol. 1993, 264:C866-C874.
96. Otamiri T., Franzen L., Lindmark D., Tagesson C. Increased phospholipase A2 and decreased lysophospholipase activity in the small intestinal mucosa after ischaemia and revascularisation. Gut 1987, 28:1445-1453.
97. Otamiri T., Tagesson C. Role of phospholipase A2 and oxygenated free radicals in mucosal damage after small intestinal ischemia and reperfusion. Am. J. Surg. 1989, 157:562-565. (discussion 566).
98. Das D.K., Engelman R.M., Otani H., Rousou J.A., Breyer R.H., Lemeshow S. Effect of superoxide dismutase and catalase on myocardial energy metabolism during ischemia and reperfusion. Clin. Physiol. Biochem. 1986, 4:187-198.
99. Shaikh N.A., Downar E. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ. Res. 1981, 49:316-325.
100. Kawaguchi H., Shoki M., Iizuka K., Sano H., Sakata Y., Yasuda H. Phospholipid metabolism and prostacyclin synthesis in hypoxic myocytes. Biochim. Biophys. Acta 1991, 1094:161-167.
101. Drgova A., Likavcanova K., Dobrota D. Changes of phospholipid composition and superoxide dismutase activity during global brain ischemia and reperfusion in rats. Gen. Physiol. Biophys. 2004, 23:337-346.
102. Block E.R., Patel J.M., Edwards D. Mechanism of hypoxic injury to pulmonary artery endothelial cell plasma membranes. Am. J. Physiol. 1989, 257:C223-C231.
103. Bhat G.B., Block E.R. Effect of hypoxia on phospholipid metabolism in porcine pulmonary artery endothelial cells. Am. J. Physiol. 1992, 262:L606-L613.
104. Oudot F., Cordelet C., Sergiel J.P., Grynberg A. Polyunsaturated fatty acids influence prostanoid synthesis in vascular endothelial cells under hypoxia and reoxygenation. Int. J. Vitam. Nutr. Res. 1998, 68:263-271.
105. Cunningham T.J., Yao L., Lucena A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties. J. Inflamm. 2008, 5:17.
106. Tagesson C., Franzen L., Dahl G., Westrom B. Lysophosphatidylcholine increases rat ileal permeability to macromolecules. Gut 1985, 26:369-377.
107. Otamiri T., Sjodahl R., Tagesson C. Lysophosphatidylcholine potentiates the increase in mucosal permeability after small-intestinal ischaemia. Scand. J. Gastroenterol. 1986, 21:1131-1136.
108. Pacheco S., Hillier K., Smith C. Increased arachidonic acid levels in phospholipids of human colonic mucosa in inflammatory bowel disease. Clin. Sci. (Lond.) 1987, 73:361-364.
109. Morita H., Nakanishi K., Dohi T., Yasugi E., Oshima M. Phospholipid turnover in the inflamed intestinal mucosa: arachidonic acid-rich phosphatidyl/plasmenyl-ethanolamine in the mucosa in inflammatory bowel disease. J. Gastroenterol. 1999, 34:46-53.
110. Kramer J.H., Dickens B.F., Misik V., Weglicki W.B. Phospholipid hydroperoxides are precursors of lipid alkoxyl radicals produced from anoxia/reoxygenated endothelial cells. J. Mol. Cell. Cardiol. 1995, 27:371-381.
111. Bishop W.R., Bell R.M. Assembly of phospholipids into cellular membranes: biosynthesis, transmembrane movement and intracellular translocation. Annu. Rev. Cell Biol. 1988, 4:579-610.
112. Baranska J. Biosynthesis and transport of phosphatidylserine in the cell. Adv. Lipid Res. 1982, 19:163-184.
113. Seigneuret M., Devaux P.F. ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:3751-3755.
114. Morrot G., Herve P., Zachowski A., Fellmann P., Devaux P.F. Aminophospholipid translocase of human erythrocytes: phospholipid substrate specificity and effect of cholesterol. Biochemistry 1989, 28:3456-3462.
115. Connor J., Pak C.H., Zwaal R.F., Schroit A.J. Bidirectional transbilayer movement of phospholipid analogs in human red blood cells. Evidence for an ATP-dependent and protein-mediated process. J. Biol. Chem. 1992, 267:19412-19417.
116. Beleznay Z., Zachowski A., Devaux P.F., Navazo M.P., Ott P. ATP-dependent aminophospholipid translocation in erythrocyte vesicles: stoichiometry of transport. Biochemistry 1993, 32:3146-3152.
117. Julien M., Tournier J.F., Tocanne J.F. Basic fibroblast growth factor modulates the aminophospholipid translocase activity present in the plasma membrane of bovine aortic endothelial cells. Eur. J. Biochem. 1995, 230:287-297.
118. Andrick C., Broring K., Deuticke B., Haest C.W. Fast translocation of phosphatidylcholine to the outer membrane leaflet after its synthesis at the inner membrane surface in human erythrocytes. Biochim. Biophys. Acta 1991, 1064:235-241.
119. Wiedmer T., Zhou Q., Kwoh D.Y., Sims P.J. Identification of three new members of the phospholipid scramblase gene family. Biochim. Biophys. Acta 2000, 1467:244-253.
120. Francis V.G., Mohammed A.M., Aradhyam G.K., Gummadi S.N. The single C-terminal helix of human phospholipid scramblase 1 is required for membrane insertion and scrambling activity. FEBS J. 2013, 280:2855-2869.
121. Sahu S.K., Gummadi S.N., Manoj N., Aradhyam G.K. Phospholipid scramblases: an overview. Arch. Biochem. Biophys. 2007, 462:103-114.
122. Sims P.J., Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb. Haemost. 2001, 86:266-275.
123. Bevers E., Comfurius P., Zwaal R.F.A. Regulatory mechanisms in maintenance and modulation of transmembraane lipid asymmetry: pathophysiologic implications. Lupus 1996, 5:480-487.
124. Williamson P., Kulick A., Zachowski A., Schlegel R.A., Devaux P.F. Ca2+ induces transbilayer redistribution of all major phospholipids in human erythrocytes. Biochemistry 1992, 31:6355-6360.
125. Williamson P., Bevers E.M., Smeets E.F., Comfurius P., Schlegel R.A., Zwaal R.F. Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets. Biochemistry 1995, 34:10448-10455.
126. Bevers E.M., Williamson P.L. Phospholipid scramblase: an update. FEBS Lett. 2010, 584:2724-2730.
127. Basse F., Stout J.G., Sims P.J., Wiedmer T. Isolation of an erythrocyte membrane protein that mediates Ca2+-dependent transbilayer movement of phospholipid. J. Biol. Chem. 1996, 271:17205-17210.
128. Zhou Q., Zhao J., Stout J.G., Luhm R.A., Wiedmer T., Sims P.J. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J. Biol. Chem. 1997, 272:18240-18244.
129. Stout J.G., Basse F., Luhm R.A., Weiss H.J., Wiedmer T., Sims P.J. Scott syndrome erythrocytes contain a membrane protein capable of mediating Ca2+-dependent transbilayer migration of membrane phospholipids. J. Clin. Invest. 1997, 99:2232-2238.
130. Frasch S.C., Henson P.M., Nagaosa K., Fessler M.B., Borregaard N., Bratton D.L. Phospholipid flip-flop and phospholipid scramblase 1 (PLSCR1) co-localize to uropod rafts in formylated Met-Leu-Phe-stimulated neutrophils. J. Biol. Chem. 2004, 279:17625-17633.
131. Wiedmer T., Zhao J., Nanjundan M., Sims P.J. Palmitoylation of phospholipid scramblase 1 controls its distribution between nucleus and plasma membrane. Biochemistry 2003, 42:1227-1233.
132. Sun J., Nanjundan M., Pike L.J., Wiedmer T., Sims P.J. Plasma membrane phospholipid scramblase 1 is enriched in lipid rafts and interacts with the epidermal growth factor receptor. Biochemistry 2002, 41:6338-6345.
133. Ory S., Ceridono M., Momboisse F., Houy S., Chasserot-Golaz S., Heintz D., Calco V., Haeberle A.M., Espinoza F.A., Sims P.J., Bailly Y., Bader M.F., Gasman S. Phospholipid scramblase-1-induced lipid reorganization regulates compensatory endocytosis in neuroendocrine cells. J. Neurosci. 2013, 33:3545-3556.
134. Liu J., Dai Q., Chen J., Durrant D., Freeman A., Liu T., Grossman D., Lee R.M. Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol. Cancer Res. 2003, 1:892-902.
135. Francis V.G., Majeed M.A., Gummadi S.N. Recovery of functionally active recombinant human phospholipid scramblase 1 from inclusion bodies using N-lauroyl sarcosine. J. Ind. Microbiol. Biotechnol. 2012, 39:1041-1048.
136. Sahu S.K., Aradhyam G.K., Gummadi S.N. Calcium binding studies of peptides of human phospholipid scramblases 1 to 4 suggest that scramblases are new class of calcium binding proteins in the cell. Biochim. Biophys. Acta 2009, 1790:1274-1281.
137. Stout J.G., Zhou Q., Wiedmer T., Sims P.J. Change in conformation of plasma membrane phospholipid scramblase induced by occupancy of its Ca2+ binding site. Biochemistry 1998, 37:14860-14866.
138. Sanchez-Magraner L., Posada I.M., Andraka N., Contreras F.X., Viguera A.R., Guerin D.M., Arrondo J.L., Monaco H.L., Goni F.M. The C-terminal transmembrane domain of human phospholipid scramblase 1 is essential for the protein flip-flop activity and Ca(2)(+)-binding. J. Membr. Biol. 2014, 247:155-165.
139. Frasch S.C., Henson P.M., Kailey J.M., Richter D.A., Janes M.S., Fadok V.A., Bratton D.L. Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta. J. Biol. Chem. 2000, 275:23065-23073.
140. Merregaert J., Van Langen J., Hansen U., Ponsaerts P., El Ghalbzouri A., Steenackers E., Van Ostade X., Sercu S. Phospholipid scramblase 1 is secreted by a lipid raft-dependent pathway and interacts with the extracellular matrix protein 1 in the dermal epidermal junction zone of human skin. J. Biol. Chem. 2010, 285:37823-37837.
141. Zhao J., Zhou Q., Wiedmer T., Sims P.J. Palmitoylation of phospholipid scramblase is required for normal function in promoting Ca2+-activated transbilayer movement of membrane phospholipids. Biochemistry 1998, 37:6361-6366.
142. Ben-Efraim I., Zhou Q., Wiedmer T., Gerace L., Sims P.J. Phospholipid scramblase 1 is imported into the nucleus by a receptor-mediated pathway and interacts with DNA. Biochemistry 2004, 43:3518-3526.
143. Chen M.H., Ben-Efraim I., Mitrousis G., Walker-Kopp N., Sims P.J., Cingolani G. Phospholipid scramblase 1 contains a nonclassical nuclear localization signal with unique binding site in importin alpha. J. Biol. Chem. 2005, 280:10599-10606.
144. Rami A., Sims J., Botez G., Winckler J. Spatial resolution of phospholipid scramblase 1 (PLSCR1), caspase-3 activation and DNA-fragmentation in the human hippocampus after cerebral ischemia. Neurochem. Int. 2003, 43:79-87.
145. Inuzuka T., Inokawa A., Chen C., Kizu K., Narita H., Shibata H., Maki M. ALG-2-interacting Tubby-like protein superfamily member PLSCR3 is secreted by exosomal pathway and taken up by recipient cultured cells. Biosci. Rep. 2013, 33:281-293.